"10.1371_journal.pone.0069266","plos one","2013-07-18T00:00:00Z","Anna Maria Geretti; Zoe Fox; Jeffrey A Johnson; Clare Booth; Jonathan Lipscomb; Lieven J Stuyver; Gilda Tachedjian; John Baxter; Giota Touloumi; Clara Lehmann; Andrew Owen; Andrew Phillips; for the INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group","Institute of Infection & Global Health, University of Liverpool, Liverpool, United Kingdom; Institute of Neurology, University College London, London, United Kingdom; Division of HIV/AIDS Prevention, Centers for Disease Control, Atlanta, Georgia, United States of America; Department of Virology, Royal Free London NHS Foundation Trust, London, United Kingdom; Janssen Diagnostics BVBA, Beerse, Belgium; Tachedjian Laboratory, Burnet Institute, Melbourne, Australia; Department of Infectious Diseases, Cooper University Hospital, Camden, New Jersey, United States of America; Department of Epidemiology and Statistics, Athens University Medical School, Athens, Greece; Department of Internal Medicine, University of Cologne, Cologne, Germany; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom; Institute of Epidemiology & Health, University College London, London, United Kingdom","Â¶ See Reference 1 for the complete list of SMART investigators.","Gilda Tachedjian is an academic editor for PLOS ONE. The other authors have declared that no competing interests exist. Lieven J. Stuyver is an employee of Tibotec-Virco Virology BVBA (Beerse, Belgium), a company which commercializes HIV drug resistance testing technology. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","07","Anna Maria Geretti","AMG",13,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA
